

ALOPATHY VERSUS ALTERNATIVE THERAPIES

Authors

Shah Murad, Zafar H Tanveer, Saleemullah Abro, Jamil Ahmed Lakhair, Abdul Salam, Shaheena

Professor of Pharmacology, QIMS, Quetta, Pakistan
HOD Physiology and Principal, QIMS, Quetta Pakistan
AP Physiology at BMC, Karachi Pakistan
Vice Principal, KIMS, Malir Cantt Karachi Pakistan
Professor of Pharmacology at QIMS, Quetta Pakistan
Prof of Biochemistry, KIMS, Karachi Pakistan

Corresponding Author:

MASTOI SHAH MURAD,
Pharmacology Deptt at QIMS, Quetta Balochistan, Pakistan.
shahmurad65@imdcollge.edu.pk

Article Received: 01-05-2023

Revised: 20-05-2023

Accepted: 10-06-2023

ABSTRACT:

Looking for an effective way to support balance for body and mind, turn to herbs for good health that have a long history of use. The World Health Organization (WHO) defines good health as: A state of complete physical, mental, and social well-being, rather than merely the absence of disease or infirmity. That's a very broad definition, and may differ slightly and will undoubtedly be specific to any individual. But however you define good health, taking an herbal supplement is a great way to help keep body and mind in healthy shape. Ginger originated in Island Southeast Asia and was likely domesticated first by the Austronesian peoples. It was transported with them throughout the Indo-Pacific during the Austronesian expansion, reaching as far as Hawaii. Ginger was also one of the first spices exported from the Orient, ginger arrived in Europe during the spice trade, and was used by ancient Greeks and Romans. The distantly related dicots in the genus *Asarum* are commonly called wild ginger because of their similar taste. *Zinger Officinale* (Ginger) is widely used miscellaneous nutrient in sub-continent, having antioxidant, anticancer, anti-inflammatory and anti-hyperlipidemic properties. We selected its hypolipidemic and weight lost effects in primary and secondary hyperlipidemic patients. Type of Research study: It was placebo-controlled study. Area of research: Research was conducted in Jinnah hospital, Lahore, Pakistan. Duration of study: It was three months, from January 2021 to June 2021. Material, Method and Results: Already well understood, clearly explained written consent was taken from sixty hyperlipidemic patients age range from 18 to 70 years. Both gender male and female patients were enrolled. Patients were randomly divided in two groups, 30 patients were on drug ginger pasted-powder advised to take 5 grams in divided doses with their normal diet for the period of three months. Thirty patients were on placebo pasted-wheat powder, with same color as of ginger powder, advised to take 5 grams in divided doses with their normal diet for the period of three months. Their base line lipid profile and body weight was recorded at start of treatment and were advised to come for check-up, fortnightly. When duration of study was over, their lipid profile and body weight was measured and compared statistically with pre-treatment values. Three months treatment with 5 grams of Ginger decreased LDL-cholesterol 17.41%, total-cholesterol 8.83% and body weight 2.11%. When compared with placebo group, all changes in mentioned parameters were significant biostatistically. Conclusion: It was concluded from results of study that active ingredients of ginger lower plasma lipids and body weight significantly, eventually preventing development of coronary artery disease in primary and secondary hyperlipidemic patients.

Keywords: *body weight, lipids, blood pressure, CAD, prevention*

INTRODUCTION:

Hyperlipidemia is pathological state of body leading to cardiac complications. Cardiovascular diseases and stroke are complication of hyperlipidemia, diabetes mellitus, hypertension, ¹. Many hypolipidemic drugs

have already been proved to be useful in lowering serum lipid levels in patients. However, its side effects in long term treatment were more reported and its prices were still expensive. Thus, efforts to develop effective and better hypolipidemic drugs had led to the discovery of

natural medicinal herbs². The beneficial uses of medicinal plants in traditional system of medicine of many cultures are extensively documented³. Several plants have been used as dietary adjuvant and in treating the number of diseases even without any knowledge on their proper functions and constituents⁴. Over 80% of the world population uses natural remedies as medicine and over 70% of doctors in Germany prescribe plant-based medicines⁵. Ginger (*Zingiber officinale*) is a natural dietary component, which has hypolipidemic, antiplatelet aggregation, antioxidant and anticarcinogenic properties⁶. Ginger is indigenous to southern China, spreading eventually to the Spice Islands, other parts of Asia and subsequently to West Africa and the Caribbean⁷. Ginger was exported to Europe via India in the first century AD as a result of the lucrative spice trade. India remains the largest producer of ginger⁸. Hypolipidemic and antiplatelet therapy is an effective approach for preventing coronary heart disease⁹. Ginger components are suggested as a potential new class of platelet-activation inhibitors without the potential side effects of aspirin, which is most commonly used in this approach. In a comparison of gingerols and analogs with aspirin, ginger compounds were found to be less potent compared to aspirin in inhibiting arachidonic acid-induced platelet release and aggregation and COX activity. However, several analogs had a significant inhibitory effect, suggesting that further development of more potent gingerol analogs might have value as an alternative to aspirin therapy in preventing ischemic heart disease^{10,11}. Mechanism by which ginger may lower cholesterol is well understood by scientists and other researchers. They explain that ginger activates an enzyme that increases body's use of cholesterol and lowers it. Several studies show that ginger can lower experimentally induced high cholesterol in animals, but more studies on ginger's effect on humans with high cholesterol are needed before the substance can be touted as a treatment for high cholesterol. Gingerol. Gingerol is the active component of ginger and has been shown to inhibit platelet aggregation and prevent ADP release by dose-dependently inhibiting COX-1 activity. 107 In fact, gingerol was more potent than aspirin at inhibiting platelet aggregation, and it also showed antiulcer activity. Another research indicated that consuming 1600 mg of ginger for 12 weeks, significantly reduces fasting plasma glucose, HbA1C, insulin, HOMA, triglyceride, and total cholesterol compared to the placebo group¹².

MATERIAL AND METHODS:

Place of study and duration: Research study was conducted at Jinnah hospital Lahore Pakistan, from January 2021 to June 2021. **CONSENT:** Written consent was taken from sixty hyperlipidemic patients age range from 18 to 70 years. Both gender male and female patients were enrolled. **DIVISION:** Patients were randomly divided in two groups, 30 patients were on drug ginger pasted-powder advised to take 5 grams in divided doses with their normal diet for the period of three months. Thirty patients were on placebo pasted-wheat powder, with same color as of ginger powder, advised to take 5 grams in divided doses with their normal diet for the period of three months. Their base line lipid profile (for total serum cholesterol, LDL-cholesterol) and body weight was recorded at start of treatment and were advised to come for check-up, fortnightly. **BIOSTATISTICAL CALCULATION:** When duration of study was over, their lipid profile and body weight was measured and compared statistically with pre-treatment values. Serum total cholesterol was estimated by the enzymatic calorimatic method. Serum LDL-cholesterol was calculated by Friedwald formula⁵ (LDL-Cholesterol = Total Cholesterol-(Triglycerides/5 +HDL-Cholesterol). Body weight was determined by conventional method of usual weight machine Data were expressed as the mean \pm SD and paired "t" test was applied to determine statistical significance as the difference. A probability value of <0.05 was considered as non-significance and $P<0.001$ was considered as highly significant change in the results.

RESULTS:

Three months treatment with 5 grams of Ginger reduced LDL-cholesterol from 185.21 ± 2.01 to 157.72 ± 1.90 mg/dl, which is highly significant change in the parameter (p-value <0.001). Serum total cholesterol at baseline was 251.11 ± 2.00 mg/dl, which reduced to 230.71 ± 1.77 mg/dl. This change is highly significant statistically, with p-value <0.001 . Mean body weight decreased from $79.01\pm$ kg to 77.32 ± 2.61 kg in three months therapy. All changes are highly significant statistically, having p-value <0.001 . In placebo group LDL-Cholesterol, serum total cholesterol and body weight reduction was 0.18, 0.77, and 0.22 % respectively. All these changes are non-significant (p-value >0.05). Detailed changes are shown in following tables:

TABLE:1, showing pretreatment, post treatment values, change in percentage and their statistical significance in DRUG GROUP (n=27)

Parameter	Pretreatment	Post-treatmentr	Change in %	p-value
LDL-c	185.21±2.01	157.72± 1.90	17.41%	<0.001
T-C	251.11±2.00	230.71±1.77	8.83%	<0.001
Body weight	79.01±3.01	77.32±2.61	2.11%	<0.05

TABLE:2, showing pretreatment, post treatment values, change in percentage and their statistical significance in PLACEBO GROUP (n=30)

Parameter	Pretreatment	Post-treatment	Change in %	p-value
LDL-c	143.25±1.99	142.98±2.61	0.18%	>0.05
Tc	190.47±2.71	188.99±2.50	0.77%	>0.05
Body weight	76.73±2.19	76.56±2.71	0.22%	>0.05

KEY: ± indicates standard error of mean, p-value >0.05 indicates non significant and P<0.001 indicates highly significant change in lipid profile. LDL-C means low density lipoprotein cholesterol mg/dl, T-C means total serum cholesterol mg/dl, and body weight is measured in kg.

DISCUSSION:

Ginger possesses anti-cancer, anti-clotting, anti-inflammatory, and anti-oxidative characteristics, since it can scavenge superoxide anion and hydroxyl radicals. In our research study ginger was used in thirty male and female hyperlipidemic patients for three months, which reduced LDL-cholesterol from baseline value of 185.21±2.01 mg/dl to 157.72 ±1.90 mg/dl. It is 17.4% change in this parameter, which is highly significant change statistically with p-value of <0.001. These results match with results of Bordia A et al¹³ who mentioned

that nearly same effects of ginger may be achieved when the drug is used for three months. He has mentioned detailed explanations regarding effects of ginger in hyperlipidemic and hyperglycemic conditions. These results are in contrast with study results of Thomson M et al¹⁴ who observed less effect on LDL-cholesterol, i.e.; from 179.57±2.29 mg/dl to 176.92±2.11 mg/dl when they used three grams of ginger for the period of 6 months in 82 hyperlipidemic subjects. These variations and too much contrast in these two comparable studies may be sample size, long duration of

administration of chemical compound/drug. In our observation serum total cholesterol reduced from 251.11±2.00 mg/dl to 230.71±1.77 mg/dl. Vaes LP and Chyka PA¹⁵ observed almost same changes in serum total cholesterol when they used 2 grams ginger powder, twice daily for the period of one month. Their results augment and support results of our research work. Our results in the parameter also match with results of study conducted by Chrubasek S et al¹⁶ who observed same changes in serum total cholesterol. Five grams of ginger in our study reduced body weight of 30 male/female patients from 79.01± kg to 77.32±2.61 kg by 3 months therapy. Nurtjahja-Tjendraputra E et al¹⁷ also observed same changes by their research study. This proves and augments our research results. Fuhrman B et al¹⁸ described presence of various chemical ingredients in ginger which are responsible to decrease high levels of serum lipid levels and decreased blood pressure in hyperlipidemic patients. Our results are in contrast with study results of Guh J H et al¹⁹ who proved that there is no significant effect on body weight when 2 grams of ginger powder daily was used for two months, in one hundred volunteers having secondary hyperlipidemia. Possible and guessed, scientific reason for this difference may be type of hyperlipidemia, ie; we included both primary and secondary hyperlipidemic patients, and they only included secondary hyperlipidemic patients²⁰⁻²⁴.

REFERENCES:

1. PE Schurr. Triton – induced hyperlipidemia in rats as an animal model for screening hyperlipidemic drugs. *Lipids*. 2006; 7, 68-74.
2. Farmer JA, Torre-Amione G. Comparative tolerability of the HMG-CoA reductase inhibitors. *Drug Saf*.2000;23:197–213.
3. Kumar G, Srivastava A, Sharma SK, Gupta YK. Safety evaluation of an Ayurvedic medicine, Arogyavardhini vati on brain, liver and kidney in rats. *J Ethnopharmacol*. 2012;140:151–60.
4. Ramachandran A, Snehalatha C, Satyavani K, Sivasankari S, Vijay V. Metabolic syndrome in urban Asian Indian adults: A population study using modified ATP III criteria. *Diabetes Res Clin Pract*.2003;60:199–204.
5. A.P. Kourounakis, P. Victoratos, N, Perulis, N. Stefanou, M. Jiangou, L.Hadjipetrou, P.N.Kourounakis (2002). Experimental hyperlipidemia and the effect of NSAIDs . *Experimental and Molecular Pathology*. 2002: 73, 135-138.
6. Ellen RL, McPherson R. Long-term efficacy and safety of fenofibrate and a statin in the treatment of combined hyperlipidemia. *Am J Cardiol*. 1998;81:60B–5.
7. Lipscombe J, Lewis GF, Cattran D, Bargman JM. Deterioration in renal function associated with fibrate therapy. *Clin Nephrol*. 2001;55:39–44.
8. Kluft C, de Maat MP, Gevers Leuven JA, Potter van Loon BJ, Mohrschladt MF. Statins and C-reactive protein. *Lancet*. 1999;353:1274.
9. Lagrand WK, Visser CA, Hermens WT, Niessen HW, Verheugt FW, Wolbink GJ, et al. C-reactive protein as a cardiovascular risk factor: More than an epiphenomenon? *Circulation*. 1999;100:96–102.
10. I-Min Liu, Shorong-Shii Liou, Ting-Wei Lan, Feng-Lin Hsu, Juei-Tang Cheng. Myricetin as the active principle of *Abelmoschus moschatus* to lower plasma glucose in streptozotocin-induced diabetic rats. *Planta Med*. 2005: 71 (7), 617-621.
11. Kahlon. In vitro binding of bile acids by okra, beets, asparagus, eggplant, turnips, green beans, carrots, and cauliflower. *Food chemistry*. 2007: 103 (2), 676-680.
12. Fuhrman B, Rosenblat M, Hayek T, Coleman R, Aviram M. Ginger extract consumption reduces plasma cholesterol, inhibits LDL oxidation, and attenuates development of atherosclerosis in atherosclerotic, apolipoprotein E-deficient mice. *J Nutr*. 2000;130(5):1124-1131.
13. Bordia A, Verma SK, Srivastava KC. Effect of ginger (*Zingiber officinale* Rosc.) and fenugreek (*Trigonella foenumgraecum* L.) on blood lipids, blood sugar, and platelet aggregation in patients with coronary heart disease. *Prostaglandins Leukot Essent Fatty Acids*. 1997;56(5):379-384.
14. Thomson M, Al Qattan KK, Al Sawan SM, et al. The use of ginger (*Zingiber officinale* Rosc.) as a

potential anti-inflammatory and antithrombotic agent. *Prostaglandins Leukot Essent Fatty Acids*. 2002;67(6):475-478.

15. Vaes LP, Chyka PA. Interactions of warfarin with garlic, ginger, ginkgo, or ginseng: nature of the evidence. *Ann Pharmacother*. 2000;34(12):1478-1482.

16. Chrubasik, S., Pittler, M. H., and Roufogalis, B. D. *Zingiberis rhizoma*: a comprehensive review on the ginger effect and efficacy profiles. *Phytomedicine* 2005;12(9):684-701.

17. Nurtjahja-Tjendraputra, E., Ammit, A. J., Roufogalis, B. D., Tran, V. H., and Duke, C. C. Effective anti-platelet and COX-1 enzyme inhibitors from pungent constituents of ginger. *Thromb.Res* 2003;111(4-5):259-265.

18. Fuhrman, B., Rosenblat, M., Hayek, T., Coleman, R., and Aviram, M. Ginger extract consumption reduces plasma cholesterol, inhibits LDL oxidation and attenuates development of atherosclerosis in atherosclerotic, apolipoprotein E-deficient mice. *J Nutr* 2000;130(5):1124-1131.

19. Guh, J. H., Ko, F. N., Jong, T. T., and Teng, C. M. Antiplatelet effect of gingerol isolated from *Zingiber officinale*. *J Pharm.Pharmacol*. 1995;47(4):329-332.

20. Ellen RL, McPherson R. Long-term efficacy and safety of fenofibrate and a statin in the treatment of combined hyperlipidemia. *Am J Cardiol*. 1998;81:60B-5.

21. Lipscombe J, Lewis GF, Cattran D, Bargman JM. Deterioration in renal function associated with fibrate therapy. *Clin Nephrol*. 2001;55:39-44.

22. Kluft C, de Maat MP, Gevers Leuven JA, Potter van Loon BJ, Mohrschladt MF. Statins and C-reactive protein. *Lancet*. 1999;353:1274.

23. Lagrand WK, Visser CA, Hermens WT, Niessen HW, Verheugt FW, Wolbink GJ, et al. C-reactive protein as a cardiovascular risk factor: More than an epiphenomenon? *Circulation*. 1999;100:96-102.

24. I-Min Liu, Shorong-Shii Liou, Ting-Wei Lan, Feng-Lin Hsu, Juei-Tang Cheng. Myricetin as the active principle of *Abelmoschus moschatus* to lower plasma glucose in streptozotocin-induced diabetic rats. *Planta Med*. 2005; 71 (7), 617-621.